ArticleThe Journal of infectious diseases2021
Mechanisms of Colonization Resistance Against Clostridioides difficile.
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Washed Microbiota Transplantation for Clostridioides Difficile Infection: a Real World Research
CMTS0929 for Clostridioides Difficile Infection: a Prospective, Open-label, Single-arm Clinical Study
Who cites it
40 citing papers in PubMed.
- Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrentGut microbes · 2025Trial
- Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection.The Journal of infectious diseases · 2025Trial
- Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-Open forum infectious diseases · 2024Trial
- Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.Infectious diseases and therapy · 2026Review
- Saccharomyces cerevisiae 48338 Suppresses Antibiotic-Induced Clostridioides difficile Infection in a Murine Model.Probiotics and antimicrobial proteins · 2026Article
- Altitude-Associated Divergence of the Gut Microbiome in Endangered Forest Musk Deer: Evidence From Integrated Metagenomics, Metabolomics, and Culturomics.Evolutionary applications · 2026Article
- Re-evaluating gut microbiome signatures of post-antibiotic dietary fiber intake in a large adult cohort.BMC research notes · 2026Article
- A set of genetic tools for use inMicrobiology (Reading, England) · 2026Article
- The Intestinal Barrier: A Multilayered Gatekeeper Against Systemic Disease.International journal of microbiology · 2026Review
- Successful fecal microbiota transplants in post-antibiotic treated recurrentGut microbes reports · 2026Article
- MMETHANE: interpretable AI for predicting host status from microbial composition and metabolomics data.Microbiome · 2025Article
- Successful Fecal Microbiota Transplants in Post-antibiotic Treated RecurrentResearch square · 2025Article
- Resource diversity and supply drive colonization resistance.PLoS computational biology · 2025Article
- Intersections of ABO blood group, secretor status, and the gut microbiome: implications for disease susceptibility and therapeutics.Archives of microbiology · 2025Review
- Dietary Fiber Modulates the Window of Susceptibility to Clostridioides difficile Infection.Gastroenterology · 2025Article
- Article
- Caffeic acid phenethyl ester protectseLife · 2025Article
- Clostridioides difficile concentration-dependant alterations in gut microbiota of asymptomatic infants.Gut pathogens · 2025Article
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clostridioides difficile is an urgent antimicrobial-resistant bacterium, causing mild to moderate and sometimes life-threatening disease. Commensal gut microbes are critical for providing colonization resistance against C difficile and can be leveraged as non-antibiotic alternative therapeutics for the prevention and treatment of C difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.